ECM
FBRX icon

ExodusPoint Capital Management’s Forte Biosciences FBRX Stock Holding History

ExodusPoint Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$356K Buy
13,747
+2,663
+24% +$76.7K ﹤0.01% 1275
2025
Q4 		$302K Buy
+11,084
New +$194K ﹤0.01% 1311
2021
Q2 		– Sell
-1,801
Closed -$1.54M – 2490
2021
Q1 		$1.54M Buy
1,801
+608
+51% +$498K 0.02% 686
2020
Q4 		$1.09M Buy
+1,193
New +$1.12M 0.01% 806

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

ExodusPoint Capital Management's FBRX Position: Q1 2026 in Review

ExodusPoint Capital Management increased its Forte Biosciences (FBRX) stake by 24% in Q1 2026, buying an estimated $76.7K and bringing the position to 13,747 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #1275.

ExodusPoint Capital Management first reported a position in FBRX in Q4 2020 and has held it in 4 quarters since. The position peaked at $1.54M in Q1 2021. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • ExodusPoint Capital Management held 13,747 shares of Forte Biosciences worth $356K as of Q1 2026.
  • ExodusPoint Capital Management bought 2,663 Forte Biosciences shares in Q1 2026, an estimated $76.7K.
  • Forte Biosciences made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1275 holding.
  • ExodusPoint Capital Management first reported a position in Forte Biosciences in Q4 2020 and has held it in 4 quarters since.
  • ExodusPoint Capital Management's Forte Biosciences position peaked at $1.54M in Q1 2021.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.